Immunohistochemistry utilization in the diagnosis of melanoma

Dinehart, Matthew S.; Dinehart, Scott M.; Sukpraprut‐Braaten, Suporn; High, Whitney A.

doi:10.1111/cup.13648

Cited by 25 publications

(28 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immunohistochemical markers are commonly used alongside histopathologic examination but remain subjective, especially for proliferation markers. 12,[36][37][38][39][40] CGH leverages the genome instability typical of melanomas and surveys the entire genome for copy number abnormalities that correlate with clinical behavior. 41,42 Extraction of adequate DNA from small biopsies or shave biopsies can be challenging.…”

Section: Melanoma Diagnostic Testing Technologiesmentioning

confidence: 99%

Diagnosis of melanoma by imaging mass spectrometry: Development and validation of a melanoma prediction model

et al. 2021

View full text Add to dashboard Cite

Background: The definitive diagnosis of melanocytic neoplasia using solely histopathologic evaluation can be challenging. Novel techniques that objectively confirm diagnoses are needed. This study details the development and validation of a melanoma prediction model from spatially resolved multivariate protein expression profiles generated by imaging mass spectrometry (IMS). Methods: Three board-certified dermatopathologists blindly evaluated 333 samples. Samples with triply concordant diagnoses were included in this study, divided into a training set (n = 241) and a test set (n = 92). Both the training and test sets included various representative subclasses of unambiguous nevi and melanomas. A prediction model was developed from the training set using a linear support vector machine classification model. Results:We validated the prediction model on the independent test set of 92 specimens (75 classified correctly, 2 misclassified, and 15 indeterminate). IMS detects melanoma with a sensitivity of 97.6% and a specificity of 96.4% when evaluating each unique spot. IMS predicts melanoma at the sample level with a sensitivity of 97.3% and a specificity of 97.5%. Indeterminate results were excluded from sensitivity and specificity calculations. Conclusion:This study provides evidence that IMS-based proteomics results are highly concordant to diagnostic results obtained by careful histopathologic evaluation from a panel of expert dermatopathologists.

show abstract

Section: Melanoma Diagnostic Testing Technologiesmentioning

confidence: 99%

Diagnosis of melanoma by imaging mass spectrometry: Development and validation of a melanoma prediction model

et al. 2021

View full text Add to dashboard Cite

show abstract

“…A standard histological staining against hematoxylin and eosin (H&E) was done and the samples were observed using a light microscope. [59][60][61]…”

Section: Immunohistochemistry Analysismentioning

confidence: 99%

Fabrication of Carboxymethyl Chitosan Nanoparticles to Deliver Paclitaxel for Melanoma Treatment

et al. 2020

View full text Add to dashboard Cite

In the present study, the effectiveness of paclitaxel nanocrystals (PTX NCs) encapsulated in carboxymethyl chitosan (CMCS) nanoparticles (CMCS−PTX NPs) as an anticancer drug is evaluated. The CMCS nanoparticles are produced via a cross‐junction microfluidic device where the PTX/CMCS concentration and flow rates in the device are optimized. The dynamic light scattering data show that the PTX NCs have a median diameter size of 230±90 nm, while the size of CMCS−PTX NPs is roughly 270±30 nm. The zeta‐potential result indicates less negative surface charge for the CMCS−PTX NPs as compared to the PTX NCs. Moreover, scanning electron microscopy micrographs, differential scanning calorimetry thermograms, and X‐ray diffraction patterns reveal that the physicochemical properties of the drug remain unaltered after perfusion through the microfluidic device. Cytotoxicity and cell endocytosis of PTX NCs and CMCS−PTX NPs are evaluated in vitro using G361 melanoma‐positive skin cells. The results reveal that the CMCS−PTX NPs increase the cellular uptake and cytotoxicity compared to the PTX NCs alone. In addition, the antitumor effect of CMCS−PTX NPs on B16 melanoma indicates the great potential of CMCS as a promising nano‐carrier for PTX NCs drug with potent inhibitory effect on the tumor growth.

show abstract

“…In the early 1980s, S100 was first identified as a useful melanocytic marker expressing a high sensitivity approaching 100%, and it is commonly expressed in all subtypes of melanoma, including desmoplastic melanoma. A large number of other melanocytic markers have been subsequently investigated including HMB45, Melan A, tyrosinase, MITF, and SOX10, and are increasingly used in the diagnosis of melanoma [1][2][3]. Nevertheless, rare cases of malignant melanoma can present with unusual staining patterns.…”

Section: Introductionmentioning

confidence: 99%

Aberrant Expression of Immunohistochemical Markers in Malignant Melanoma: A Review

Saliba

Bhawan

2021

Dermatopathology

View full text Add to dashboard Cite

Immunohistochemical stains are increasingly used to aid in the diagnosis of malignant melanoma, especially when the differentiation of the tumor is unclear based on examination with hematoxylin and eosin. However, aberrant expression of non-melanocytic markers has been reported in melanomas, which can sometimes be further complicated by the loss of conventional melanocytic markers. This review aims to summarize available data regarding unusual staining patterns in primary and metastatic malignant melanoma. It also raises awareness of the potential pitfalls and highlights the importance of appropriate use and interpretation of broad immunohistochemical markers in the context of clinical and histopathologic findings to facilitate the diagnosis of atypical cases of malignant melanoma.

show abstract

Immunohistochemistry utilization in the diagnosis of melanoma

Cited by 25 publications

References 9 publications

Diagnosis of melanoma by imaging mass spectrometry: Development and validation of a melanoma prediction model

Diagnosis of melanoma by imaging mass spectrometry: Development and validation of a melanoma prediction model

Fabrication of Carboxymethyl Chitosan Nanoparticles to Deliver Paclitaxel for Melanoma Treatment

Aberrant Expression of Immunohistochemical Markers in Malignant Melanoma: A Review

Contact Info

Product

Resources

About